...
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients.
【24h】

Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients.

机译:比较0.5%的阿普拉可乐定和4%的可卡因在儿科患者霍纳综合征的诊断中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to compare the efficacy of 0.5% apraclonidine with that of 4% cocaine and to evaluate its safety in the diagnosis of Horner syndrome in pediatric patients. METHODS: This was a randomized, crossover study, wherein 10 patients with a probable diagnosis of Horner syndrome were assigned to undergo pharmacological testing with 4% cocaine and 0.5% apaconidine. The difference in the pupil diameters of each eye was recorded under dim light before and 1 h after 0.5% apraclonidine or 4% cocaine was instilled. Any adverse effects were noted during examination or reported by the patients' parents were recorded. RESULTS: The mean differences in pupil diameter before and after 4% cocaine testing were -2.08 and -2.97 mm, respectively (P = 0.0047). All patients had an anisocoria greater than 1 mm after 4% cocaine testing. The mean difference in pupil diameter before and after 0.5% apraclonidine was instilled were -2.04 and +1.08 mm, respectively (P = 0.005). All patients showed a reversal of anisocoria after 0.5% apraclonidine testing. Conjunctival hyperemia was noted in 2 patients, but systemic adverse effects were not noted during examination nor reported by the patients' parents. CONCLUSIONS: The application of 0.5% apraclonidine in pediatric patients is safe and effective in the diagnosis of Horner syndrome.
机译:目的:这项研究的目的是比较0.5%apraclonidine和4%可卡因的疗效,并评估其在儿科患者Horner综合征诊断中的安全性。方法:这是一项随机,交叉研究,其中10名可能诊断为霍纳综合症的患者被分配接受4%可卡因和0.5%阿帕考定的药理学测试。在昏暗的灯光下,在滴入0.5%阿普拉可尼定或4%可卡因之前和之后1小时,记录每只眼睛的瞳孔直径差异。在检查过程中注意到任何不良反应,或记录患者父母的报告。结果:在进行4%可卡因测试之前和之后,瞳孔直径的平均差异分别为-2.08和-2.97 mm(P = 0.0047)。在进行4%可卡因测试后,所有患者的各向异性均大于1 mm。滴注0.5%阿普拉克隆定前后瞳孔直径的平均差分别为-2.04和+1.08 mm(P = 0.005)。 0.5%的阿普拉可尼定测试后,所有患者均表现出各向异性的逆转。 2例患者发现结膜充血,但检查期间未发现全身不良反应,患者父母也未报告。结论:0.5%的阿普拉可乐定在小儿患者中的应用是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号